Acyclovir (Aciclovir)

別名：Acycloguanosine, ACV, NSC 645011,BW 248U

製品コード：S1807 純度：99.93%

Acyclovir (Aciclovir) is a synthetic nucleoside analogue active against herpesviruses. Acyclovir induces cell cycle perturbation and apoptosis in Jurkat leukemia cells.

CAS No. 59277-89-3

サイズ	価格(税別)	在庫状況
10mM (1mL in DMSO)	JPY 23500	国内在庫あり
50mg	JPY 18100	国内在庫あり
1g	JPY 101400	国内在庫なし(納期7~10日)

代表番号: 045-509-1970\|電子メール：[email protected] よく尋ねられる質問

文献中Selleckの製品使用例（16）

カスタマーフィードバック1个实验数据

製品安全説明書

現在のバッチを見る：純度： 99.93%

99.93

Acyclovir (Aciclovir)関連製品

関連化合物ライブラリー	Anti-infection Compound Library Antibiotics compound Library Antiviral Compound Library Anti-parasitic Compound Library Gut Microbial Metabolite Library	もっと見る

Antiviral阻害剤の選択性比較

Cell Data

Cell Lines	Assay Type	Incubation Time	活性情報	PMID
african green monkey Vero cells	Function assay	48 h	Antiviral activity against HSV2 strain 333 infected in african green monkey Vero cells assessed as inhibition of cytopathic effect after 48 hrs by plaque reduction assay, EC50=1.87 μM	22704890
HEL cells	Function assay	4 days	Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathogenicity after 4 days, EC50=0.2 μM	22459876
African green monkey Vero 76 cells	Cytotoxicity assay	48-96 h	Cytotoxicity against African green monkey Vero 76 cells assessed as cell viability after 48 to 96 hrs by crystal violet staining, CC50=13 μM	26119992
BSC-1 cells	Function assay		Antiviral activity of the compound was evaluated against the Herpes simplex virus type-1 in BSC-1 cells, IC50=2.6 μM	2913300
P3HR-1 cells	Function assay		Effective concentration for the inhibition of Epstein-Barr virus EBV-DNA synthesis in human lymphoblastoid P3HR-1 cells, EC50=6.75 μM	12408726
HFF cells	Function assay		Concentration for HSV-1 plaque reduction (VPR) by 50% in HFF cells, EC50=1.1 μM	14584954
HFF cells	Function assay		Inhibitory concentration required to reduce HSV-1 induced cytopathogenic effect (CPE) by 50 % in HFF cells, EC50=2.22 μM	14584954
human embryonic lung cells	Function assay		Antiviral activity was measured as effective concentration required to reduce Varicella Zoster virus (OKA)-induced plaque formation in human embryonic lung cells, EC50=1.1 μM	11549457
HEL cells	Function assay		Compound was tested for anti-viral activity against HSV-1(G) in HEL cells, EC50=1.3 μM	14643328
HEL cell	Function assay		Effective concentration required to inhibit Tyrosine kinase (TK+) Varicella-Zoster virus-induced cytopathicity by 50% in OKA strain HEL cell lines, EC50=4.53 μM	11495586
HSV-2 MS Vero cells	Function assay		Inhibition of viral cytopathic effect in infected human foreskin fibroblast cell monolayers of HSV-2 MS Vero cells by 50%, EC50=6.2 μM	11585457
HSV-1 E-377 Vero cells	Function assay		Inhibition of plaque formation in monolayers of HSV-1 E-377 Vero cells by 50%, EC50=4.4 μM	11585457
HSV-1 KOS Vero cells	Function assay		Inhibition of plaque formation in monolayers of HSV-1 KOS Vero cells by 50%, EC50=2.2 μM	11585457
HeLa cell	Function assay		Ability to inhibit cytopathogenicity of herpes simplex type 1 virus (G) in HeLa cell culture, IC50=0.19 μM	11356110
HEp-2 cells	Function assay		Minimum inhibitory concentration causing 25% inhibition of cytopathic effect induced by Herpes simplex virus-1 (K979) in HEp-2 cells	2842506
HeLa cells	Function assay		Inhibition of HSV-1 DNA synthesis in virus-infected HeLa cells, IC50=1.9 μM	7752206
human HFF cells	Function assay		Inhibitory concentration of the drug against the cytopathic effect for E-377 strain of herpes simplex virus-1 (HSV-1) in human HFF cells, EC50=0.04 μM	8394933
human HFF cells	Function assay		Inhibitory concentration of the drug against the cytopathic effect for MS strain of herpes simplex virus-2 (HSV-2) in human HFF cells, EC50=0.09 μM	8394933
MRC-5 cells	Function assay		Antiviral activity in plaque reduction assay was determined against herpes simplex virus type 2 (HSV-2) in MRC-5 cells, IC50=2.5 μM	2153202
human lung fibroblasts (MRC-5)	Function assay		Compound was tested for antiviral activity against Herpes Simplex virus Type-1(18189) in human lung fibroblasts (MRC-5)	3040998
Raji cells	Function assay		Inhibitory concentration of the drug against the antigen production against P3HR-1 strain of epstein barr virus-2 (EBV) in Raji cells, EC50=2.9 μM	8394933
Vero cells	Function assay		Inhibitory activity against herpes simplex virus type 2 (HSV 2) strain 186 in Vero cells, IC50=1.7 μM	8576922
BSC-1 cells	Function assay		Effective concentration required to inhibit herpes simplex virus 1 in BSC-1 cells in ELISA, EC50=1.5 μM	15634003
HFF cells	Function assay		Effective concentration required to inhibit varicella zoster virus replication in HFF cells, EC50=1.6 μM	15634003
HFF cells	Function assay		Effective concentration required to inhibit herpes simplex virus 1 in HFF cells in cytopathic effect (CPE) assay, EC50=0.9 μM	15634003
Daudi cells	Function assay		Inhibition of EBV replication in Daudi cells by viral capsid antigen-ELISA, EC50=0.33 μM	17004726
WI-38 cell	Function assay		Anti viral activity against VZV(pplla strain) in WI-38 cell monolayers, ID50=4 μM	1316966
HEL cells	Function assay		Antiviral activity against HSV1 KOS infected in HEL cells assessed as inhibition of virus-induced cytopathic effect, EC50=0.14 μM	23099097
他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

生物活性

製品説明

Acyclovir (Aciclovir) is a synthetic nucleoside analogue active against herpesviruses. Acyclovir induces cell cycle perturbation and apoptosis in Jurkat leukemia cells.

Targets

HSV ^[1]

In Vitro
In vitro	Acyclovir sensitivity of herpes simplex virus isolates is determined in a plaque-reduction assay in Vero cells. IC50 Values are consistently 2-3 fold lower in B2 compared with the H strain of Vero cells. HSV Type 2 strains are 2-10-fold less sensitive than Type 1 strains^[2].

In Vivo
In Vivo	low-dose oral acyclovir may be effective in the prevention of HSV infection during OKT3 treatment of seropositive patients. Continuation of acyclovir prophylaxis for two to four weeks following the conclusion of OKT3 therapy may prevent occurrence of delayed infections^[3].

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
臨床試験 (data from https://clinicaltrials.gov, updated on 2024-01-11)
NCT05589688	Not yet recruiting	Obesity	University Hospital Toulouse	January 2024	Phase 1
NCT06058858	Not yet recruiting	Cytomegalovirus Infections\|Acute Leukemia\|B Cell Lymphoma	Assistance Publique - Hôpitaux de Paris	October 1 2023	--
NCT05468619	Recruiting	Herpes Simplex	National Institute of Allergy and Infectious Diseases (NIAID)	September 23 2022	Phase 1
NCT05198570	Recruiting	Herpesviridae Infections\|Herpes Simplex 1\|Varicella Zoster Virus Infection\|Transplantation Infection\|Oncology	University of Pisa\|IRCCS Burlo Garofolo	September 15 2021	--

参考
[1] Meyrick Thomas RH, et al. Br J Dermatol. 1985, 113(6):731-735. [2] Collins P, et al. J Antimicrob Chemother. 1986, 18 Suppl B:103-12. [3] Tang IY, et al. Transplant Proc. 1989, 21(1 Pt 2):1758-1760.

参考

化学情報

分子量	225.2	化学式	C₈H₁₁N₅O₃
CAS No.	59277-89-3	SDF	Download Acyclovir (Aciclovir) SDFをダウンロードする
Smiles	C1=NC2=C(N1COCCO)N=C(NC2=O)N
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1年-80°Cin solvent
保管	3年-20°C粉	溶液の保管冷凍と解凍の繰り返しを避けるため小分けにしてください	1个月-20°Cin solvent

In vitro
Batch:

DMSO : 45 mg/mL ( (199.82 mM)；吸湿したDMSOは溶解度を減少させます。新しいDMSOをご使用ください。)

Water : Insoluble

Ethanol : Insoluble

モル濃度計算器

in vivo
Batch:

Add solvents to the product individually and in order.

投与溶液組成計算機

実験計算

モル濃度計算器

質量	濃度	体積	分子量
=	×	×

希釈計算器分子量計算器

投与溶液組成計算機(クリア溶液)

ステップ１：実験データを入力してください。（実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します）

投与量 mg/kg 動物平均体重 g 投与体積（動物毎）μL 動物数匹

ステップ２：投与溶媒の組成を入力してください。（ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください）

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

計算結果：

投与溶媒濃度： mg/ml;

DMSOストック溶液調製方法： mg 試薬を μL DMSOに溶解する（濃度 mg/mL, 注：濃度が当該ロットのDMSO溶解度を超える場合はご連絡ください。 )

投与溶媒調製方法：Take μL DMSOストック溶液に μL PEG300，を加え、完全溶解後μL Tween 80，を加えて完全溶解させた後 μL ddH₂O，を加え完全に溶解させます。

投与溶媒調製方法：μL DMSOストック溶液に μL Corn oil，を加え、完全溶解。

注意：１.ストック溶液に沈殿、混濁などがないことをご確認ください；
２.順番通りに溶剤を加えてください。次のステップに進む前に溶液に沈殿、混濁などがないことを確認してから加えてください。ボルテックス、ソニケーション、水浴加熱など物理的な方法で溶解を早めることは可能です。

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):